Balixafortide

Drug Profile

Balixafortide

Alternative Names: POL-6326

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Polyphor
  • Class Antineoplastics; Cyclic peptides; Epitopes; Peptidomimetics
  • Mechanism of Action CXCR4 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Asthma; Cancer; Coronary artery restenosis; Inflammation; Stem cell mobilisation; Wounds

Highest Development Phases

  • Phase II Myocardial infarction; Stem cell mobilisation
  • No development reported Breast cancer; Coronary artery restenosis; Inflammation; Solid tumours; Wounds

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Breast-cancer(Combination therapy, Metastatic disease, Second-line therapy or greater) in Spain (IV, Infusion)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Breast-cancer(Combination therapy, Metastatic disease, Second-line therapy or greater) in USA (IV, Infusion)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Solid-tumours in Switzerland (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top